Coca-Cola vs. J&J: Defensive Stock Performance Diverges in 2026

Johnson & Johnson (NYSE:JNJ) has emerged as the dominant performer among traditional defensive stocks in 2026, with its shares climbing 35% year-to-date. This surge, driven by advancements in its oncology and immunology pipelines, saw $JNJ+WL significantly outperform the S&P 500 Index (SPY), which returned 13%, and the Invesco S&P 500 Low Volatility ETF (SPLV), which gained 6%. Coca-Cola (NYSE:KO) also surpassed the broader market with its performance.

In contrast, Procter & Gamble (PG) experienced headwinds from flat organic sales and commodity costs, resulting in a modest 4% year-to-date gain. This divergence underscores a shift in investor perception, where "defensive" may increasingly be defined by specific sector strengths rather than a blanket approach to lower volatility.

Johnson & Johnson's robust quarter included $25.3 billion in worldwide sales, a 5.6% operational increase, prompting management to raise full-year adjusted operational EPS guidance to between $11.50 and $11.65. Key drivers included Darzalex sales exceeding $4 billion with 17.6% growth, and Tremfya reaching $2 billion in quarterly sales, up 71%. The acquisition of Intra-Cellular Therapies also contributed, with Caplyta sales growing 70.9% in the second quarter.

### Story Arc / How We Got Here Coca-Cola (KO) continues to be a cornerstone of Berkshire Hathaway's portfolio under new CEO Greg Abel, maintaining its status as a long-term dividend growth play. The beverage giant's consistent dividend increases and substantial market potential offer a compelling case for patient investors. Coca-Cola's consistent dividend growth and substantial global market potential make it an attractive holding for long-term income investors.

[Visit our prior coverage on Coca-Cola: /explore/ceo-desk-coca-cola-buffett-legacy-stock-holds-under-new-leadership]